Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Nigericin sodium salt is an antibiotic, an NLRP3 activator, and a cationic ion carrier. Nigericin sodium triggers the activation of the NALP3 inflammasome, which inhibits Golgi function and suppresses the growth of Gram-positive bacteria.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 209.00 | |
50 mg | In stock | $ 312.00 | |
100 mg | In stock | $ 468.00 |
Description | Nigericin sodium salt is an antibiotic, an NLRP3 activator, and a cationic ion carrier. Nigericin sodium triggers the activation of the NALP3 inflammasome, which inhibits Golgi function and suppresses the growth of Gram-positive bacteria. |
In vitro |
METHODS: Triple-negative breast cancer cells MDA-MB-231 and 4T1 were treated with Nigericin sodium (0.25-20 μg/mL) for 24 h. The cell viability of the cells was detected by the MTS. RESULTS: Nigericin sodium dose-dependently inhibited the cell viability of MDA-MB-231 and 4T1 cells with IC50 of 2.881 μM and 2.505 μM, respectively. [1] METHODS: Human lung cancer cells H460 were treated with Nigericin sodium (1 μM) for 24-48 h. Cell migration and invasion were detected by Transwell. RESULTS: Nigericin sodium significantly inhibited the migration and invasion of H460 cells. [2] |
In vivo |
METHODS: To detect anti-tumor activity in vivo, Nigericin sodium (2 mg/kg, subcutaneous injection every two days) and anti-PD-1 (250 μg/mouse, intraperitoneal injection once a week) were administered to BALB/c mice bearing triple-negative mammary adenocarcinoma tumor 4T1 for two weeks. RESULTS: PD-1 antibody alone did not show significant antitumor effects, while Nigericin sodium showed moderate antitumor effects.The combination of Nigericin sodium and anti-PD-1 almost completely inhibited tumor growth. [1] METHODS: To investigate the effects of aging on inflammatory vesicle function, Nigericin sodium (0.005 mg/g, 250 μL) was administered as a single intraperitoneal injection once daily for seven days to influenza virus-infected BALB/c mice. RESULTS: Treatment with Nigericin sodium during influenza infection increased IL-1β production, increased capase-1 activity, and reduced morbidity and mortality in aged mice. During influenza virus infection, NLRP3 inflammatory vesicle activity is impaired in aged mice, and Nigericin sodium treatment rescues NLRP3 in aged hosts.[3] |
Molecular Weight | 746.94 |
Formula | C40H67NaO11 |
CAS No. | 28643-80-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3mg/mL(4.02 mM), Sonication is recommended.
Methanol: 122 mg/mL (163.33mM)
Ethanol: 50 mg/mL (66.94 mM), Sonication is recommended.
Ethanol: 47 mg/mL (62.92mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Nigericin sodium salt 28643-80-3 Immunology/Inflammation Membrane transporter/Ion channel Microbiology/Virology NF-Κb Potassium Channel NOD-like Receptor (NLR) Antibacterial Antibiotic NOD Inhibitor Nigericin Bacterial inhibit Nigericin sodium KcsA inhibitor